All In Biotech

Drug Trial Radar · NCT05042206

Phase 1 Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Chronic Kidney Disease

An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Nov 24, 2021

Primary completion

Sep 21, 2023

Study completion Sep 21, 2023

Sponsor

Lead sponsor
Pharmicell Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety of Cellgram-CKD in patients with chronic kidney disease over 12 months after three administrations. The main question it aims to answer is: \- What medical problems do participants have after receiving Cellgram-CKD? Participants will: \- Receive Cellgram-CKD by intravenous infusion three times at 2-week intervals. Visit the clinic 1, 3, 6, 9, and 12 months after the third administration for safety assessments.

Conditions

  • Chronic Kidney Disease

Interventions

  • Cellgram-CKDBiological

    5 × 10\^7 allogeneic bone marrow-derived mesenchymal stem cells (10 mL) administered by intravenous infusion three times at 2-week (14-day) intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From the first administration of the investigational product to 12 months after the third administration of the investigational product.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.